Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03319849 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B
A Phase 3 study, sponsored by Neurotech Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 119
- Enrollment target
NCT03319849 is a Phase 3 study that has completed, run by Neurotech Pharmaceuticals. The registered enrollment target is 119 participants.
The verdict
NCT03319849, a Phase 3 study, has completed, sponsored by Neurotech Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 119 participants
- Enrollment target
Study Summary
This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.
Interventions
- PROCEDURE Sham
- COMBINATION_PRODUCT NT-501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2018-01-22 |
| Est. Completion | 2022-09-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03319849
The ClinicalTrials.gov registry entry for NCT03319849 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurotech Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT03319849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03319849 about?
NCT03319849 is a clinical study titled "A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B". This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.
What is the current status of trial NCT03319849?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 119 participants. The study started on 2018-01-22. Estimated completion is 2022-09-23.
What interventions are being tested in trial NCT03319849?
The interventions under investigation include: Sham (PROCEDURE), NT-501 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03319849?
This trial is sponsored by Neurotech Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.